ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Outcomes in long-term survivors treated with stereotactic cranial radiotherapy for brain metastases.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to characterize long-term intracranial control, recurrence patterns, radiation necrosis (RN) risk, and treatment intensity among patients with ≥ 24 months of follow-up after stereotactic cranial radiotherapy (SRT).
methodsWe conducted a retrospective review of patients treated with SRT at a single institution from 2018 to 2023. Eligible patients received at least one course of SRT and had ≥ 104 weeks of follow-up. Clinical, treatment, and radiologic data were collected as well as in-field and out-of-field failure, RN incidence and management, survival, and treatment patterns over time.
resultsFifty-one patients met the inclusion criteria, contributing 130 SRT courses treating 241 lesions. Median follow-up was 33.8 months. Most patients (51%) had non-small cell lung cancer, and 80% received systemic therapy after initial SRT. In-field failure occurred in 16.2% of lesions and 47.1% of patients, with higher failure rates in resection cavities than in intact metastases. Out-of-field failure occurred in 47.1% of patients, most commonly managed with additional SRT. The 2‑year in-field and out-of-field recurrence-free rates were 47.7% and 56.6%, respectively. Radiation necrosis developed in 21 lesions (8.7%), with substantially higher incidence in resection cavities (29.4%) and re-irradiated targets. Median time to RN was 11.2 months, and 38% required surgical intervention. Five-year overall survival was 67.8%.
conclusionAmong long-term survivors treated with SRT, both intracranial recurrence and RN remain clinically significant. As patient survival improves, individualized surveillance, careful consideration of cumulative radiation exposure, and optimized re-irradiation strategies are essential to minimize toxicity while maintaining durable intracranial control.
Indexed as
Identifiers
42821082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.